-
1
-
-
0041411106
-
Diagnosis and treatment of systemic mastocytosis: State of the art
-
Valent P, Akin C, Sperr WR et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003 122 : 695 717.
-
(2003)
Br J Haematol
, vol.122
, pp. 695-717
-
-
Valent, P.1
Akin, C.2
Sperr, W.R.3
-
3
-
-
0036958893
-
Mastocytosis: Current concepts in diagnosis and treatment
-
Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002 81 : 677 690.
-
(2002)
Ann Hematol
, vol.81
, pp. 677-690
-
-
Escribano, L.1
Akin, C.2
Castells, M.3
Orfao, A.4
Metcalfe, D.D.5
-
4
-
-
0036207693
-
Histopathological and immunohistochemical aspects of mastocytosis
-
Horny HP, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002 127 : 115 117.
-
(2002)
Int Arch Allergy Immunol
, vol.127
, pp. 115-117
-
-
Horny, H.P.1
Valent, P.2
-
6
-
-
0028856070
-
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
-
Nagata H, Worobec AS, Oh CK et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995 92 : 10560 10564.
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 10560-10564
-
-
Nagata, H.1
Worobec, A.S.2
Oh, C.K.3
-
7
-
-
0009013631
-
Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
-
Longley BJ, Tyrrell L, Lu SZ et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996 12 : 312 314.
-
(1996)
Nat Genet
, vol.12
, pp. 312-314
-
-
Longley, B.J.1
Tyrrell, L.2
Lu, S.Z.3
-
8
-
-
13044305857
-
Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
-
Longley BJ, Metcalfe DD, Tharp M et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999 96 : 1609 1614.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 1609-1614
-
-
Longley, B.J.1
Metcalfe, D.D.2
Tharp, M.3
-
9
-
-
0035010149
-
Mutation analysis of c-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis
-
Fritsche-Polanz R, Jordan JH, Feix A et al. Mutation analysis of c-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001 113 : 357 364.
-
(2001)
Br J Haematol
, vol.113
, pp. 357-364
-
-
Fritsche-Polanz, R.1
Jordan, J.H.2
Feix, A.3
-
10
-
-
0036207241
-
Kit and c-kit mutations in mastocytosis: A short overview with special reference to novel molecular and diagnostic concepts
-
Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002 127 : 110 114.
-
(2002)
Int Arch Allergy Immunol
, vol.127
, pp. 110-114
-
-
Féger, F.1
Ribadeau Dumas, A.2
Leriche, L.3
Valent, P.4
Arock, M.5
-
11
-
-
0345772088
-
Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria
-
Valent P, Akin C, Sperr WR et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003 27 : 635 641.
-
(2003)
Leuk Res
, vol.27
, pp. 635-641
-
-
Valent, P.1
Akin, C.2
Sperr, W.R.3
-
12
-
-
37749039528
-
Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients
-
Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008 63 : 226 232.
-
(2008)
Allergy
, vol.63
, pp. 226-232
-
-
Brockow, K.1
Jofer, C.2
Behrendt, H.3
Ring, J.4
-
13
-
-
4944253841
-
On the way to targeted therapy of mast cell neoplasms: Identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts
-
Valent P, Ghannadan M, Akin C et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 2004 34 : 41 52.
-
(2004)
Eur J Clin Invest
, vol.34
, pp. 41-52
-
-
Valent, P.1
Ghannadan, M.2
Akin, C.3
-
14
-
-
19944434116
-
Mastocytosis: Pathology, genetics, and current options for therapy
-
Valent P, Akin C, Sperr WR et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005 46 : 35 48.
-
(2005)
Leuk Lymphoma
, vol.46
, pp. 35-48
-
-
Valent, P.1
Akin, C.2
Sperr, W.R.3
-
15
-
-
38549127753
-
How we diagnose and treat WHO-defined systemic mastocytosis in adults
-
Tefferi A, Verstovsek S, Pardanani A. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica 2008 93 : 6 9.
-
(2008)
Haematologica
, vol.93
, pp. 6-9
-
-
Tefferi, A.1
Verstovsek, S.2
Pardanani, A.3
-
16
-
-
27144506215
-
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
-
Gotlib J, Berubé C, Growney JD et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005 106 : 2865 2870.
-
(2005)
Blood
, vol.106
, pp. 2865-2870
-
-
Gotlib, J.1
Berubé, C.2
Growney, J.D.3
-
17
-
-
30444446680
-
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
-
Gleixner KV, Mayerhofer M, Aichberger KJ et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006 107 : 752 759.
-
(2006)
Blood
, vol.107
, pp. 752-759
-
-
Gleixner, K.V.1
Mayerhofer, M.2
Aichberger, K.J.3
-
18
-
-
33645687784
-
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
-
Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006 108 : 286 291.
-
(2006)
Blood
, vol.108
, pp. 286-291
-
-
Shah, N.P.1
Lee, F.Y.2
Luo, R.3
Jiang, Y.4
Donker, M.5
Akin, C.6
-
19
-
-
36349020293
-
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
-
Gleixner KV, Mayerhofer M, Sonneck K et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007 92 : 1451 1459.
-
(2007)
Haematologica
, vol.92
, pp. 1451-1459
-
-
Gleixner, K.V.1
Mayerhofer, M.2
Sonneck, K.3
-
20
-
-
39049130408
-
STI571 (Glivec(R)) affects histamine release and intracellular pH after alkalinisation in HMC-1(560, 816)
-
Löber K, Alfonso A, Escribano L, Botana LM. STI571 (Glivec(R)) affects histamine release and intracellular pH after alkalinisation in HMC-1(560, 816). J Cell Biochem 2008 103 : 865 876.
-
(2008)
J Cell Biochem
, vol.103
, pp. 865-876
-
-
Löber, K.1
Alfonso, A.2
Escribano, L.3
Botana, L.M.4
-
21
-
-
42449139172
-
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils
-
Kneidinger M, Schmidt U, Rix U et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008 111 : 3097 3107.
-
(2008)
Blood
, vol.111
, pp. 3097-3107
-
-
Kneidinger, M.1
Schmidt, U.2
Rix, U.3
-
22
-
-
18844478996
-
PKC412 - A protein kinase inhibitor with a broad therapeutic potential
-
Fabbro D, Ruetz S, Bodis S et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000 15 : 17 28.
-
(2000)
Anticancer Drug des
, vol.15
, pp. 17-28
-
-
Fabbro, D.1
Ruetz, S.2
Bodis, S.3
-
23
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005 7 : 129 141.
-
(2005)
Cancer Cell
, vol.7
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
-
24
-
-
0024399296
-
Interleukin 3 activates human blood basophils via high-affinity binding sites
-
Valent P, Besemer J, Muhm M, Majdic O, Lechner K, Bettelheim P. Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci USA 1989 86 : 5542 5546.
-
(1989)
Proc Natl Acad Sci USA
, vol.86
, pp. 5542-5546
-
-
Valent, P.1
Besemer, J.2
Muhm, M.3
Majdic, O.4
Lechner, K.5
Bettelheim, P.6
-
25
-
-
33947420879
-
Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab
-
Mirkina I, Schweighoffer T, Kricek F. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunol Lett 2007 109 : 120 128.
-
(2007)
Immunol Lett
, vol.109
, pp. 120-128
-
-
Mirkina, I.1
Schweighoffer, T.2
Kricek, F.3
-
26
-
-
0023950976
-
Establishment of an immature mast cell line from a patient with mast cell leukemia
-
Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988 12 : 345 355.
-
(1988)
Leuk Res
, vol.12
, pp. 345-355
-
-
Butterfield, J.H.1
Weiler, D.2
Dewald, G.3
Gleich, G.J.4
-
27
-
-
0026355821
-
IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells
-
Sillaber C, Strobl H, Bevec D et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 1991 147 : 4224 4228.
-
(1991)
J Immunol
, vol.147
, pp. 4224-4228
-
-
Sillaber, C.1
Strobl, H.2
Bevec, D.3
-
28
-
-
33644900475
-
Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells
-
Krauth MT, Majlesi Y, Sonneck K et al. Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy 2006 61 : 281 288.
-
(2006)
Allergy
, vol.61
, pp. 281-288
-
-
Krauth, M.T.1
Majlesi, Y.2
Sonneck, K.3
-
29
-
-
0036968257
-
Recombinant allergens promote expression of CD203c on basophils in sensitized individuals
-
Hauswirth AW, Natter S, Ghannadan M et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002 110 : 102 109.
-
(2002)
J Allergy Clin Immunol
, vol.110
, pp. 102-109
-
-
Hauswirth, A.W.1
Natter, S.2
Ghannadan, M.3
-
30
-
-
0033604543
-
Signaling through the high-affinity IgE receptor Fc-epsilon RI
-
Turner H, Kinet JP. Signaling through the high-affinity IgE receptor Fc-epsilon RI. Nature 1999 402 : 24 30.
-
(1999)
Nature
, vol.402
, pp. 24-30
-
-
Turner, H.1
Kinet, J.P.2
-
31
-
-
0034713675
-
Immunologically mediated signaling in basophils and mast cells: Finding therapeutic targets for allergic diseases in the human Fc-epsilon RI signaling pathway
-
Oliver JM, Kepley CL, Ortega E, Wilson BS. Immunologically mediated signaling in basophils and mast cells: finding therapeutic targets for allergic diseases in the human Fc-epsilon RI signaling pathway. Immunopharmacology 2000 48 : 269 281.
-
(2000)
Immunopharmacology
, vol.48
, pp. 269-281
-
-
Oliver, J.M.1
Kepley, C.L.2
Ortega, E.3
Wilson, B.S.4
-
32
-
-
37049014938
-
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
-
Rix U, Hantschel O, Dürnberger G et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007 110 : 4055 4063.
-
(2007)
Blood
, vol.110
, pp. 4055-4063
-
-
Rix, U.1
Hantschel, O.2
Dürnberger, G.3
-
33
-
-
1842830011
-
The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis
-
Bühring HJ, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 2004 133 : 317 329.
-
(2004)
Int Arch Allergy Immunol
, vol.133
, pp. 317-329
-
-
Bühring, H.J.1
Streble, A.2
Valent, P.3
-
34
-
-
27344453965
-
Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation
-
Hennersdorf F, Florian S, Jakob A et al. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res 2005 15 : 325 335.
-
(2005)
Cell Res
, vol.15
, pp. 325-335
-
-
Hennersdorf, F.1
Florian, S.2
Jakob, A.3
-
35
-
-
41849098106
-
Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patients
-
Sonneck K, Baumgartner C, Rebuzzi L et al. Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patients. Int J Immunopathol Pharmacol 2008 21 : 11 21.
-
(2008)
Int J Immunopathol Pharmacol
, vol.21
, pp. 11-21
-
-
Sonneck, K.1
Baumgartner, C.2
Rebuzzi, L.3
|